ViroGates announces that the development and regulatory approval of the suPARnostic\u00ae TurbiLatex product for Roche Diagnostics cobas c500 and c700 series has been completed. The suPARnostic\u00ae TurbiLatex product is a\u00a0latex particle-enhanced turbidimetric immunoassay. The\u00a0Roche cobas c500 and c700 series are the market leading instruments\u00a0for performing immunochemical analysis in the hospitals across Europe. According to Roche Diagnostics, more than 20,000 cobas instruments are installed worldwide, each with a throughput volume of up to 1,000 tests per hour. suPARnostic\u00ae Turbilatex enables\u00a0automatic handling of blood samples at clinical chemistry laboratories,\u00a0and now all commercially relevant instruments within the Roche Diagnostic cobas series will be able to run\u00a0suPARnostic\u00ae TurbiLatex tests. Validation on other turbidimetric platforms will follow.